Antimicrobial site dressings

• US 20070293800A1
• Filed: 04/25/2007
• Published: 12/20/2007
• Est. Priority Date: 04/28/2006
• Status: Active Grant

• Current Assignee: Virchow Biotech Inc., Virchow Biotech Pvt. Ltd. (Virchow Group)
• Original Assignee: Kimberly-Clark Worldwide Incorporated (Kimberly-Clark Corporation)
• Inventors: Gibbins, Bruce, McMaken, Jack
• Granted Patent: US 8,293,965 B2
• Time in Patent Office: Days
• US Class Current: 602/48
• CPC Class Codes: A61L 15/44 Medicaments
• CPC Class Codes: A61L 2300/104 Silver, e.g. silver sulfadiazine
• CPC Class Codes: A61L 2300/236 Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
• CPC Class Codes: A61L 2300/252 Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
• CPC Class Codes: A61L 2300/404 Biocides, antimicrobial agents, antiseptic agents
• CPC Class Codes: A61L 2300/406 Antibiotics
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61M 2025/0266 using pads, patches, tapes or the like

Abstract

The present invention comprises antimicrobial articles for use with a percutaneous device, comprising a matrix which may contact the percutaneous device in a three-dimensional mode and release antimicrobial agents (e.g., silver ions) to the percutaneous device access site. In addition, the antimicrobial article of the present invention may donate moisture to a dry dermal site (e.g., a dry wound bed) and/or absorb liquid or exudates of a dermal site. The present invention also comprises methods for treating and/or preventing an infection using the antimicrobial articles of the present invention.

Claims

1. An article of manufacture for use with a percutaneous device, comprising a matrix, wherein the matrix comprises a first passage, a second passage, and an antimicrobial agent, wherein the first passage connects to the second passage, and wherein the matrix contacts a percutaneous device in a three-dimensional mode.

2. The article of claim 1, wherein the antimicrobial agent is a silver containing compound.

3. The article of claim 1, further comprising at least one active agent.

4. The article of claim 3, wherein the active agent is an antimicrobial agent, antifungal agent, antibacterial agent, anti-viral agents, antiparasitic agent, anaesthetic, mucopolysaccharide, growth factor, protein, angiogenic factor, wound healing agent or adjuvant, or combinations thereof.

5. The article of claim 4, wherein the antimicrobial agent is isoniazid, ethambutol, pyrazinamide, streptomycin, clofazimine, rifabutin, fluoroquinolones, ofloxacin, sparfloxacin, rifampin, azithromycin, clarithromycin, dapsone, tetracycline, erythromycin, ciprofloxacin, doxycycline, ampicillin, amphotericin B, ketoconazole, fluconazole, pyrimethamine, sulfadiazine, clindamycin, lincomycin, pentamidine, atovaquone, paromomycin, diclazaril, acyclovir, trifluorouridine, foscarnet, penicillin, gentamicin, ganciclovir, iatroconazole, miconazole, Zn-pyrithione, silver salts of chloride, bromide, iodide or periodate.

6. The article of claim 4, wherein the growth factor is basic fibroblast growth factor, acidic fibroblast growth factor, nerve growth factor, epidermal growth factor, insulin-like growth factors 1 and 2, platelet derived growth factor, tumor angiogenesis factor, vascular endothelial growth factor, corticotropin releasing factor, transforming growth factors alpha. and .beta., interleukin-8, granulocyte-macrophage colony stimulating factor, interleukins, or interferons.

7. The article of claim 4, wherein the mucopolysaccharide is heparin, heparin sulfate, heparinoids, dermatan sulfate, pentosan polysulfate, chondroitin sulfate, hyaluronic acid, cellulose, agarose, chitin, dextran, carrageenin, linoleic acid, or allantoin.

8. The method of claim 4, wherein the protein is collagen, cross-linked collagen, fibronectin, laminin, elastin, cross-linked elastin, antibodies, or combinations or fragments thereof.

9. The article of claim 1, wherein the matrix is made from a natural or synthetic hydrophilic polymer.

10. The article of claim 9, wherein the polymer is collagen, animal hide, hyaluronic acid, dextran, alginate, hydrophilic fibers of cross-linked and/or non-cross-linked celluloses, carboxymethy cellulose, hydroxymethyl cellulose, cotton, rayon, fibers made from polyacrylates, fibers of calcium alginates, polyacrylamide, polyvinyls, PVP, PVC, polyacrylate, polybuterate, polyurethane foam, silicone elastomer, rubber, nylon, vinyl, and cross linked dextran.

11. A method of treating or preventing an infection, comprising contacting a percutaneous device and a percutaneous device access site with an antimicrobial article, wherein the article comprises a matrix, wherein the matrix comprises a first passage, a second passage, and an antimicrobial agent, wherein the first passage connects to the second passage, and wherein the antimicrobial article contacts the percutaneous device in a three-dimensional mode.

12. The method of claim 11, wherein the antimicrobial agent is a silver containing compound.

13. The method of claim 11, further comprising at least one active agent in the matrix.

14. The method of claim 13, wherein the active agent is an antimicrobial agent, antifungal agent, antibacterial agent, anti-viral agent, antiparasitic agent, anaesthetic, mucopolysaccharide, growth factor, protein, angiogenic factor, wound healing agent or adjuvant, or combinations thereof.

15. The method of claim 14, wherein the antimicrobial agent is isoniazid, ethambutol, pyrazinamide, streptomycin, clofazimine, rifabutin, fluoroquinolones, ofloxacin, sparfloxacin, rifampin, azithromycin, clarithromycin, dapsone, tetracycline, erythromycin, ciprofloxacin, doxycycline, ampicillin, amphotericin B, ketoconazole, fluconazole, pyrimethamine, sulfadiazine, clindamycin, lincomycin, pentamidine, atovaquone, paromomycin, diclazaril, acyclovir, trifluorouridine, foscarnet, penicillin, gentamicin, ganciclovir, iatroconazole, miconazole, Zn-pyrithione, silver salts of chloride, bromide, iodide or periodate.

16. The method of claim 14, wherein the growth factor is basic fibroblast growth factor, acidic fibroblast growth factor, nerve growth factor, epidermal growth factor, insulin-like growth factors 1 and 2, platelet derived growth factor, tumor angiogenesis factor, vascular endothelial growth factor, corticotropin releasing factor, transforming growth factors alpha. and beta., interleukin-8, granulocyte-macrophage colony stimulating factor, interleukins, or interferons.

17. The article of claim 14, wherein the mucopolysaccharide is heparin, heparin sulfate, heparinoids, dermatan sulfate, pentosan polysulfate, chondroitin sulfate, hyaluronic acid, cellulose, agarose, chitin, dextran, carrageenin, linoleic acid, or allantoin.

18. The method of claim 14, wherein the protein is collagen, cross-linked collagen, fibronectin, laminin, elastin, cross-linked elastin, antibodies, or combinations or fragments thereof.

19. The article of claim 11, wherein the matrix is made from a natural or synthetic hydrophilic polymer.

20. The article of claim 19, wherein the polymer is collagen, animal hide, hyaluronic acid, dextran, alginate, hydrophilic fibers of cross-linked and/or non-cross-linked celluloses, carboxymethy cellulose, hydroxymethyl cellulose, cotton, rayon, fibers made from polyacrylates, fibers of calcium alginates, polyacrylamide, polyvinyls, PVP, PVC, polyacrylate, polybuterate, polyurethane foam, silicone elastomer, rubber, nylon, vinyl, and cross linked dextran.